Skip to main content
. 2021 Jun 28;20:130. doi: 10.1186/s12933-021-01316-4

Table 4.

Prescribing of SGLT-2is in type 2 diabetes; multilevel logistic regression model (clustered at the practice level)

Characteristic OR 95% CI p-value
Age (years) 0.98 0.975–0.979  < 0.001
Gender
 Female 1.00 [Reference]
 Male 1.13 1.083–1.185  < 0.001
Ethnicity
 White 1.00 [Reference]
 Asian 0.88 0.806–0.954 0.002
 Black 0.60 0.522–0.683  < 0.001
 Mixed 0.66 0.521–0.843  < 0.001
 Other 0.75 0.597–0.939 0.012
IMD Quintile
 1 (most deprived) 0.95 0.871–1.044 0.300
 2 0.99 0.907–1.071 0.737
 3 1.00 0.922–1.079 0.953
 4 1.01 0.937–1.088 0.795
 5 (least deprived) 1.00 [Reference]
BMI category (kg/m2)a
 Underweight 0.21 0.083–0.549 0.001
 Normal 1.00 [Reference]
 Overweight 2.05 1.841–2.274  < 0.001
 Obese 3.84 3.472–4.250  < 0.001
eGFR (mL/min/1.73m2)
  < 45 0.03 0.011–0.080  < 0.001
 45–59 0.18 0.145–0.224  < 0.001
  ≥ 60 1.00 [Reference]
Comorbidities
 Heart failure 0.81 0.653–0.998 0.048
 CVD 0.69 0.636–0.739  < 0.001
Other covariates
 Systolic BP (mmHg) 1.00 0.996–0.999 0.001
 HbA1c (mmol/mol) 1.03 1.029–1.031  < 0.001
 Diuretic 0.74 0.682–0.804  < 0.001

OR odds ratio, BMI body mass index, BP blood pressure, CVD cardiovascular disease, HbA1c glycated haemoglobin, IMD Index of Multiple Deprivation

aBMI categories closest to first SGLT-2- prescription: underweight, < 18.5 kg/m2; normal, 18.5–24.9 kg/m2; overweight, 25.0–29.9 kg/m2; obese, ≥ 30 kg/m2